fy15-17 defense medical research and development program (dmrdp)
the fy17 jpc-2/midrp is seeking research focused on combat-related or trauma-induced wound infection, specifically involving the following areas. additional information regarding focus areas will be available when the program announcements are released.
applied research:
- development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (mdros) and nosocomial pathogens, and/or characterization of antimicrobial resistance patterns.
- development of assays for host immune response biomarkers for diagnosis or prognosis.
- development and preclinical testing of novel chemotypes (chemical classes/materials), biologics as potential therapeutics or prophylactics for wound infection, and/or biofilm formation, maintenance, or propagation.
- evaluation of optimum preventive or directive therapies for combat-related or trauma-induced wound infections using food and drug administration-approved drugs, biologics, or devices either alone or in combination.
- evaluation of a functional prototype device or assay for the rapid detection of pathogens and/or microbial drug resistance markers.
- evaluation of a functional prototype device or assay for the rapid detection of novel and specific in vivo or in vitro biomarkers (from wound, serum, saliva, or urine) that predict development of infection or discriminate between infection and colonization.
- independent investigators at all academic levels (or equivalent).
- both intramural and extramural investigators are encouraged to apply.
- a pre-application is required
- the fy17 mid-ara intent is to support hypothesis-testing and/or proof-of-concept studies in in vitro and/or in vivo models, concept refinement, product candidate evaluation, maturation and/or down-selection, or completion of studies in support of ind/ide applications.
- the anticipated funding limit is $2.0m total costs.
- the anticipated maximum period of performance is 3 years.
- independent investigators at all academic levels (or equivalent). both intramural and extramural investigators are encouraged to apply.
- a pre-application is required
- the fy17 mid-cta intent is to support early phase clinical trials and medical device (including diagnostics) testing with the potential to have a major impact on prevention and treatment of combat-related or trauma induced wound infections.
- the anticipated funding limit is $2.5m total costs.
- the anticipated maximum period of performance is 3 years.